Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.

ABSTRACT:

Background

Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear.

Objective

To determine whether anticoagulation is superior to placebo in reducing death and thromboembolic complications among patients discharged after COVID-19 hospitalization.

Design

Prospective, randomized, double-blind, placebo-controlled clinical trial. (ClinicalTrials.gov: NCT04650087).

Setting

Done during 2021 to 2022 among 127 U.S. hospitals.

Participants

Adults aged 18 years or older hospitalized with COVID-19 for 48 hours or more and ready for discharge, excluding those with a requirement for, or contraindication to, anticoagulation.

Intervention

2.5 mg of apixaban ve

SUBMITTER: Wang TY 

PROVIDER: S-EPMC10064277 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature